Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CRISPR Therapeutics AG's ROE % for the quarter that ended in Jun. 2026 was -20.48%. CRISPR Therapeutics AG's PB Ratio for the quarter that ended in Jun. 2026 was 3.02.
CRISPR Therapeutics AG's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2026 was -6.78%.
CRISPR Therapeutics AG ROE % Adjusted to Book Value Related Terms
CRISPR Therapeutics AG ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for CRISPR Therapeutics AG's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG ROE % Adjusted to Book Value Chart
CRSP vs MANE, EWTX, CAI: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -6.78% mean?
CRISPR Therapeutics AG (CRSP) has a ROE % Adjusted to Book Value of -6.78% as of Jun. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's ROE % Adjusted to Book Value too high?
CRISPR Therapeutics AG's current ROE % Adjusted to Book Value is -6.78%. Overall, CRISPR Therapeutics AG has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's ROE % Adjusted to Book Value compare to MANE and EWTX?
CRISPR Therapeutics AG's ROE % Adjusted to Book Value of -6.78% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current ROE % Adjusted to Book Value is -6.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
CRISPR Therapeutics AG (CRSP) has a current ROE % Adjusted to Book Value of -6.78%. The current ROE % Adjusted to Book Value is -6.78%. CRISPR Therapeutics AG's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For CRISPR Therapeutics AG (CRSP), the current ROE % Adjusted to Book Value is -6.78% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
32GF Score
Get the complete analysis for CRSP
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRSP has been successfully added to your 
